title: LPI-labile plasma iron in iron overload.
abstract: Labile plasma iron (LPI) represents a component of non-transferrin-bound iron (NTBI) that is both redox-active and chelatable, capable of permeating into organs and inducing tissue iron overload. It appears in various types of hemosiderosis (transfusional and non-transfusional) and in other iron-overload conditions. Sustained levels of LPI could over time compromise organ (e.g. heart) function and patient survival. With the advent of methods for measuring LPI in the clinical setting, it has become possible to assess the implications of LPI in the management of iron overload based on regimens of iron chelation. As LPI is detected primarily in patients with transfusional iron overload and other forms of hemosiderosis, we review here regimens of iron chelation with deferrioxamine and deferiprone (separately or combined) in terms of their efficacy in minimizing daily exposure to LPI in thalassemia major and thalassemia intermedia patients.
authors.affiliation: Department of Biological Chemistry, Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, 91904 Israel. ioav@cc.huji.ac.il
authors.forename: Z Ioav
authors.initials: ZI
authors.lastname: Cabantchik
authors.forename: William
authors.initials: W
authors.lastname: Breuer
authors.forename: G
authors.initials: G
authors.lastname: Zanninelli
authors.forename: P
authors.initials: P
authors.lastname: Cianciulli
mesh_terms: D000077543:Deferiprone; D006801:Humans; D007501:Iron / Q000097:blood* / Q000378:metabolism; D007502:Iron Chelating Agents / Q000378:metabolism / Q000627:therapeutic use; D019190:Iron Overload / Q000378:metabolism*; D010084:Oxidation-Reduction; D011728:Pyridones / Q000627:therapeutic use; D013789:Thalassemia / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D017086:beta-Thalassemia / Q000097:blood / Q000188:drug therapy
chemical_list: D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D007501:Iron